Search

Displaying results 1971 - 1980 of 10000 in total
  1. Drug

    Vigabatrin

    go.drugbank.com/drugs/DB01080
    ApprovedInvestigational

    [A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent. … Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms.

  2. Drug

    Asparagine

    go.drugbank.com/drugs/DB00174
    ApprovedNutraceuticalWithdrawn

    (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed) … A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase.

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSION
  3. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy. … Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.

  4. Drug

    Periciazine

    go.drugbank.com/drugs/DB01608
    Approved

    It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. … It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness.

  5. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.

  6. Drug

    Tetrabenazine

    go.drugbank.com/drugs/DB04844
    Approved

    FDA approved on August 15, 2008. … A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders.

  7. Drug

    Eucalyptol

    go.drugbank.com/drugs/DB03852
    ApprovedInvestigationalNutraceutical

    Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. … Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Sulindac

    go.drugbank.com/drugs/DB00605
    ApprovedInvestigational

    Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. … Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes.

  9. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024. … Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013.

  10. Drug

    Aurothioglucose

    go.drugbank.com/drugs/DB09121
    ApprovedWithdrawn

    Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis [A32326].